Physician profile
Alexander Grand
NPI 1861694077
$5,167.19
in general payments reported to CMS, 2019-2025
21 companies · $918 in 2025
The $918 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $360 · 2021: $1,040 · 2022: $942 · 2023: $1,007 · 2024: $579 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $910.52 | 2022-2025 | Miebo, Vyzulta, Scoutpro Osmolarity System |
| Abbvie INC. | $702.10 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $609.10 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $555.61 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $476.60 | 2019-2025 | Cequa |
| Alcon Vision LLC | $436.25 | 2022-2025 | Tryptyr, Acrysof Iq Panoptix Uv Iol, Rocklatan |
| Allergan, INC. | $291.62 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $252.83 | 2021-2024 | Acthar |
| Horizon Therapeutics Plc | $145.62 | 2020-2023 | Uplizna |
| Tarsus Pharmaceuticals, INC. | $138.93 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $132.80 | 2022-2025 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $110.05 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $106.29 | 2019-2022 | |
| Biotissue Holdings INC. | $60.76 | 2024 | |
| Harrow Eye, LLC | $54.41 | 2025 | Vevye |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $50.41 | 2021 | |
| Merz Pharmaceuticals, LLC | $44.33 | 2021 | |
| Glaukos Corporation | $25.08 | 2025 | Idosetr |
| Carl Zeiss Meditec USA, INC. | $24.78 | 2024 | Cirrus Hd-Oct |
| Dompe US, INC. | $19.76 | 2025 | Oxervate |
| Rxsight INC | $19.34 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Grand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.